Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
Presentation
Title: | CRB-601, an avβ8 blocking antibody, prevents activation of TGFβand exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment |
Authors: | Daqing Wang, Ph.D; Vaishali Shinde, MS; Maneesh Singh, Ph.D.; Rachael Brake, Ph.D.; Andrew Kolodziej, Ph.D. |
Date & Time: | May 3, 2023 at 4:30pm Eastern Time |
About Corbus
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' current pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, the Company's compliance with Nasdaq's continued listing criteria and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including whether the Company will be able to regain and maintain compliance with Nasdaq's continued listing criteria, the potential impact of the COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Sean.moran@corbuspharma.com
Bruce Mackle Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-latest-pre-clinical-data-on-crb-601-av8-blocking-antibody-at-the-new-york-academy-of-sciences-frontiers-in-cancer-immunotherapy-meeting-301811475.html
SOURCE Corbus Pharmaceuticals
